Gastrointestinal Diseases Drug Development Pipeline Review, 2018

Click to copyhttps://apnews.com/7ac3c601b39e44e8b53ae03ac10315b0

DUBLIN–(BUSINESS WIRE)–Jan 11, 2019–The “Gastrointestinal Diseases Drug Development Pipeline Review 2018” report has been added to ResearchAndMarkets.com’s offering.

Gastrointestinal Diseases Drug Development Pipeline Review, 2018 provides an overview of the pipeline landscape for gastrointestinal diseases.

It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for gastroenteritis, enterocolitis, gastritis and peritonitis, and features dormant and discontinued products.

Gastroenteritis: There are 12 products in development for this indication.
Enterocolitis: There are 8 products in development for this indication.
Gastritis: There are 11 products in development for this indication.
Peritonitis: There are 7 products in development for this indication.

Molecular targets in development for gastrointestinal diseases include toll-like receptors, interleukin receptors and bacterial proteins. Companies operating in this pipeline space include Kyowa Hakko Kirin, RedHill Biopharma and GlaxoSmithKline.

Scope

Which companies are the most active within each pipeline?
Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
What are the most important R&D milestones and data publications to have happened in this disease area?

Topics Covered

1 Table of Contents

2 Introduction

3 Therapeutics Development

4 Therapeutics Assessment

5 Companies Involved in Therapeutics Development

6 Dormant Projects

7 Discontinued Products

8 Product Development Milestones

Companies Profiled

Avexegen Therapeutics Inc
BCWorld Pharm Co Ltd
Daewon Pharm Co Ltd
Daewoong Pharmaceutical Co Ltd
GlaxoSmithKline Plc
Infant Bacterial Therapeutics AB
Kyowa Hakko Kirin Co Ltd
Leadiant Biosciences Inc
Medicago Inc
Nosopharm SAS
Ology Bioservices Inc
Oncodesign SA
ProMetic Life Sciences Inc
Recce Ltd
RedHill Biopharma Ltd
Regeneron Pharmaceuticals Inc
Sequella Inc
SynAct Pharma AB
Takeda Pharmaceutical Co Ltd
UMN Pharma Inc
Vaxart Inc

For more information about this report visit https://www.researchandmarkets.com/research/vjw5x7/gastrointestinal?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190111005122/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug
Discovery,Gastrointestinal
Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/11/2019 05:47 AM/DISC: 01/11/2019 05:47 AM

http://www.businesswire.com/news/home/20190111005122/en